Updated Jul 16, 2026
Khan Najat has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $381K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | S — Open-market sale | 23.6K | $3.58 | $84K |
| 2026-05-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | F — Tax withholding / forfeiture | 62.7K | $3.04 | $191K |
| 2026-03-11 | RXRX | RECURSION PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 28.3K | $3.35 | $95K |
| 2026-02-20 | RXRX | RECURSION PHARMACEUTICALS, INC. | F — Tax withholding / forfeiture | 14.3K | $3.49 | $50K |
| 2026-02-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | F — Tax withholding / forfeiture | 10.4K | $3.98 | $41K |
| 2026-02-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | A — Grant or award | 30.3K | $0.00 | |
| 2026-02-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | A — Grant or award | 1.67M | $0.00 | |
| 2025-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | S — Open-market sale | 36.6K | $5.52 | $202K |
| 2025-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | F — Tax withholding / forfeiture | 3.8K | $5.64 | $21K |
Khan Najat is a corporate insider — currently tracked as CEO and President, Director of RECURSION PHARMACEUTICALS, INC. (RXRX). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($381K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Khan Najat profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.